Journal Article

Antiviral therapy: Valacyclovir Treatment of Alzheimer’s Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial

Devanand, D P, Stern, Yaakov, Kreisl, William C, Acosta, Edward, Andrews, Howard, Razlighi, Qolamreza, Huey, Edward D, Wisniewski, Thomas, Mintz, Akiva, Prasad, K M, Katsikoumbas, Mariasofia, Gershon, Anne, Pollina, Julianna, Bell, Karen L, Deliyannides, Deborah, Pelton, Gregory H

2020

Overview

IntroductionAfter infection, herpes simplex virus-1 (HSV1) becomes latent in the trigeminal ganglion and can enter the brain via retrograde axonal transport. Recurrent reactivation of HSV1 may lead to neurodegeneration and Alzheimer’s disease (AD) pathology. HSV1 (oral herpes) and HSV2 (genital herpes) can trigger amyloid beta-protein (Aβ) aggregation and HSV1 DNA is common in amyloid plaques. Anti-HSV drugs reduce Aβ and phosphorylated tau accumulation in cell-culture models. Cognitive impairment is greater in patients with HSV seropositive, and antiviral drugs show robust efficacy against peripheral HSV infection. Recent studies of electronic health records databases demonstrate that HSV infections increase dementia risk, and that antiviral medication treatment reduces this risk. The generic antiviral drug valacyclovir was superior to placebo in improving memory in a schizophrenia pilot trial but has not been tested in AD.Methods and analysisIn patients with mild AD who test positive for HSV1 or HSV2 serum antibodies, valacyclovir, repurposed as an anti-AD drug, will be compared with placebo (lactose pills) in 130 patients (65 valacyclovir and 65 placebo) in a randomised, double-blind, 78-week phase II proof-of-concept trial. Patients on valacyclovir, dose-titrated from 2 g to a targeted oral dose of 4 g daily, compared with placebo, are hypothesised to show smaller cognitive and functional decline, and, using 18F-Florbetapir positron emission tomography (PET) and 18F-MK-6240 PET imaging, to show less amyloid and tau accumulation, respectively. In the lumbar puncture subsample, cerebrospinal fluid acyclovir will be assayed to assess central nervous system valacyclovir penetration.Ethics and disseminationThe trial is being overseen by the New York State Psychiatric Institute Institutional Review Board (protocol 7537), the National Institute on Ageing, and the Data Safety Monitoring Board. Written informed consent is obtained for all subjects. Results will be disseminated via publication, clinicaltrials.gov, media and conferences.Trial registration numberClinicalTrials.gov identifier (NCT03282916) Pre-results.

• Publisher: BMJ Publishing Group LTD,BMJ Publishing Group
• Subject: Alzheimer Disease - drug therapy / Alzheimer Disease - virology / Alzheimer's disease / Amyloid beta-Peptides - metabolism / Antiviral Agents - therapeutic use / Antiviral drugs / Brain / Cardiovascular disease / Cognition & reasoning / Cognitive ability / Cognitive Dysfunction - virology / Dementia / Deoxyribonucleic acid / DNA / DNA polymerase / Double-Blind Method / Double-blind studies / Drug dosages / Female / Herpes Simplex - complications / Herpes Simplex - drug therapy / Herpes viruses / Herpesvirus 1, Human - drug effects / Humans / Infections / Male / Memory / Middle Aged / Mild cognitive impairment / Neurology / Older people / Proteins / Psychosis / Randomized Controlled Trials as Topic / Schizophrenia / tau Proteins - metabolism / Valacyclovir - therapeutic use / Virus Replication - drug effects